Manipulating Gene Expression in the Dyskinesias of Parkinson's Disease

操纵帕金森病运动障碍中的基因表达

基本信息

  • 批准号:
    9305587
  • 负责人:
  • 金额:
    $ 4.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-08-01 至 2018-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This project addresses one of the most disabling complications of dopaminergic therapy in Parkinson's disease, namely the development of involuntary movements named dyskinesias. The mechanisms underlying dyskinesias remain unknown, and we lack specific and effective treatments to eradicate them. Studies in animal models have shown that the striatal levels of the chronic transcription factor ΔFosB consistently increase during chronic levodopa treatment. Therefore, it has been hypothesized that ΔFosB may regulate the genes responsible for altered responses to dopaminergic drugs. Here, we will test the effects of the transgenic manipulation of ΔFosB protein expression in non-human primates. The novel approach taken in this project may address pathophysiologic aspects and help develop new therapies. The project includes three specific aims. In the first aim, we will assess the behavioral and molecular changes following the overexpression of ΔFosB in the striatum of parkinsonian monkeys using a viral vector-mediated gene delivery. The second aim will examine the basal ganglia circuitry of these animals using electrophysiologic recordings and correlate them with the development of dyskinesias. And the third aim will confirm the role of ΔFosB by down-regulating the expression of the endogenous gene in rats and monkeys. This project employs diverse experimental approaches across disciplines to address an important health problem. From the construction of viral vectors, to the in vitro testing, to the final evaluations of motor behavior and physiologic correlates in primates, this sequence of translational studies is designed to establish the mechanistic role of ΔFosB in the development of dyskinesias. Furthermore, these studies will assess the clinical application of ΔFosB gene silencing as a therapeutic strategy in complicated Parkinson's disease.
描述(申请人提供):这个项目解决了帕金森氏症多巴胺能治疗中最具致残性的并发症之一,即称为运动障碍的不自主运动的发展。运动障碍的潜在机制仍然不清楚,我们缺乏具体和有效的治疗方法来根除它们。在动物模型中的研究表明,在慢性左旋多巴治疗期间,纹状体慢性转录因子ΔFosB的水平持续上升。因此,有人推测ΔFosB可能调控导致多巴胺能药物反应改变的基因。在这里,我们将测试ΔFosB蛋白在非人类灵长类动物中表达的转基因操作的效果。在这个项目中采用的新方法可能解决病理生理学方面的问题,并有助于开发新的治疗方法。该项目包括三个具体目标。在第一个目标中,我们将使用病毒载体介导的基因传递来评估ΔFosB在帕金森病猴纹状体内过表达后的行为和分子变化。第二个目标是使用电生理记录检查这些动物的基底节回路,并将它们与运动障碍的发展联系起来。第三个目标将通过下调大鼠和猴子体内内源性基因的表达来证实ΔFosB的作用。该项目采用不同学科的不同实验方法来解决一个重要的健康问题。从病毒载体的构建,到体外测试,再到对灵长类动物运动行为和生理相关性的最终评估,这一系列翻译研究旨在确定ΔFosB在运动障碍发展中的机制作用。此外,这些研究将评估ΔFosB基因沉默作为复杂帕金森病治疗策略的临床应用。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Letter from the Editor-in-Chief: Growth of the Journal.
主编的来信:期刊的成长。
Silica-coated magnetic nanoparticles impair proteasome activity and increase the formation of cytoplasmic inclusion bodies in vitro.
  • DOI:
    10.1038/srep29095
  • 发表时间:
    2016-07-05
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Phukan G;Shin TH;Shim JS;Paik MJ;Lee JK;Choi S;Kim YM;Kang SH;Kim HS;Kang Y;Lee SH;Mouradian MM;Lee G
  • 通讯作者:
    Lee G
Silica-coated magnetic-nanoparticle-induced cytotoxicity is reduced in microglia by glutathione and citrate identified using integrated omics.
  • DOI:
    10.1186/s12989-021-00433-y
  • 发表时间:
    2021-11-25
  • 期刊:
  • 影响因子:
    10
  • 作者:
    Shin TH;Manavalan B;Lee DY;Basith S;Seo C;Paik MJ;Kim SW;Seo H;Lee JY;Kim JY;Kim AY;Chung JM;Baik EJ;Kang SH;Choi DK;Kang Y;Mouradian MM;Lee G
  • 通讯作者:
    Lee G
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

M. Maral Mouradian其他文献

M. Maral Mouradian的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('M. Maral Mouradian', 18)}}的其他基金

PME-1: Pathogenetic Role and Therapeutic Opportunity in Neurodegenerative Mixed Proteinopathies
PME-1:神经退行性混合蛋白病的致病作用和治疗机会
  • 批准号:
    10595891
  • 财政年份:
    2023
  • 资助金额:
    $ 4.8万
  • 项目类别:
Alzheimer’s Disease Protection by Reduced Adenylyl Cyclase Type 5
通过减少 5 型腺苷酸环化酶来预防阿尔茨海默病
  • 批准号:
    10526756
  • 财政年份:
    2022
  • 资助金额:
    $ 4.8万
  • 项目类别:
Role of Transglutaminase 2 in Synucleinopathies
转谷氨酰胺酶 2 在突触核蛋白病中的作用
  • 批准号:
    10285001
  • 财政年份:
    2021
  • 资助金额:
    $ 4.8万
  • 项目类别:
Training in Translating Neuroscience to Therapies
将神经科学转化为治疗的培训
  • 批准号:
    10442401
  • 财政年份:
    2021
  • 资助金额:
    $ 4.8万
  • 项目类别:
Training in Translating Neuroscience to Therapies
将神经科学转化为治疗的培训
  • 批准号:
    10204266
  • 财政年份:
    2021
  • 资助金额:
    $ 4.8万
  • 项目类别:
Training in Translating Neuroscience to Therapies
将神经科学转化为治疗的培训
  • 批准号:
    10621360
  • 财政年份:
    2021
  • 资助金额:
    $ 4.8万
  • 项目类别:
PP2A Dysregulation in the Pathogenesis of alpha-Synucleinopathies
α-突触核蛋白病发病机制中的 PP2A 失调
  • 批准号:
    9920223
  • 财政年份:
    2017
  • 资助金额:
    $ 4.8万
  • 项目类别:
Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinson's Diseas
咖啡成分对帕金森病的协同神经保护机制
  • 批准号:
    8700581
  • 财政年份:
    2012
  • 资助金额:
    $ 4.8万
  • 项目类别:
Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinson's Diseas
咖啡成分对帕金森病的协同神经保护机制
  • 批准号:
    8368832
  • 财政年份:
    2012
  • 资助金额:
    $ 4.8万
  • 项目类别:
Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinson's Diseas
咖啡成分对帕金森病的协同神经保护机制
  • 批准号:
    8543640
  • 财政年份:
    2012
  • 资助金额:
    $ 4.8万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 4.8万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 4.8万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了